MEK5 promotes lung adenocarcinoma

Lung cancer represents the leading cause of cancer death worldwide [1]. Because of that, intense efforts are being devoted to the development of novel therapeutic strategies to fight the disease [2]. In this respect, identification of new oncogenic drivers offers therapeutic opportunities in tumours in which those molecules or other cooperating elements play a pathophysiological role. Here we show that the MEK5 mitogen-activated protein kinase kinase has a pivotal role in lung cancer. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Ortiz-Ruiz has nothing to disclose. Conflict of interest: Dr. Re-Louhau has nothing to disclose. Conflict of interest: Dr. Ramos has nothing to disclose. Conflict of interest: Dr. Blanco-Munez has nothing to disclose. Conflict of interest: Dr. Ludena has nothing to disclose. Conflict of interest: Dr. Abad has nothing to disclose. Conflict of interest: Dr. Sanchez-Martin has nothing to disclose. Conflict of interest: Dr. Pandiella has nothing to disclose. Conflict of interest: Dr. Esparis-Ogando has nothing to disclose. Conflict of interest: Dr. Sanchez-Fdez has nothing to disclose.